8-K: Cara Therapeutics Regains Nasdaq Compliance on Minimum Bid Price, Faces Ongoing Stockholders' Equity Challenge

Cara Therapeutics has regained compliance with Nasdaq's minimum bid price requirement but still needs to address a stockholders' equity deficiency.

Summary

• Cara Therapeutics received a notification from Nasdaq on February 1, 2024, for not maintaining a minimum closing bid price of $1.00 per share.
• The company was initially given until July 30, 2024, to regain compliance, which was later extended to January 27, 2025.
• To regain compliance, Cara Therapeutics implemented a one-for-twelve reverse stock split, which was approved by shareholders on June 4, 2024, and became effective on December 31, 2024.
• On January 16, 2025, Nasdaq confirmed that Cara Therapeutics had regained compliance with the minimum bid price requirement after the stock price closed at or above $1.00 for ten consecutive business days.
• However, Cara Therapeutics is still not in compliance with the minimum stockholders' equity requirement, which was $707,000 as of September 30, 2024, below the required $2.5 million.
• Nasdaq has granted an extension until May 19, 2025, for Cara Therapeutics to regain compliance with the stockholders' equity requirement.
• The company's plan to regain compliance includes a proposed merger with Tvardi Therapeutics, Inc., which is expected to close on January 14, 2025.
• The merger will result in a change of control and the combined company will need to meet initial listing requirements, including a higher minimum bid price and stockholders' equity.
• There is no guarantee that the company will regain compliance with the stockholders' equity requirement or maintain its listing on the Nasdaq Capital Market.

Sentiment

Score: 4

Explanation: The document highlights both positive and negative aspects. While the company has regained compliance with the minimum bid price, the ongoing issue with stockholders' equity and the risk of delisting create a negative sentiment. The proposed merger is a positive step, but its success is not guaranteed.

Positives

• Cara Therapeutics has successfully regained compliance with the Nasdaq minimum bid price requirement.
• The company has been granted an extension until May 19, 2025, to regain compliance with the stockholders' equity requirement.
• The proposed merger with Tvardi Therapeutics, Inc. is expected to help the company meet the stockholders' equity requirement.

Negatives

• Cara Therapeutics is still not in compliance with the minimum stockholders' equity requirement.
• There is no guarantee that the company will regain compliance with the stockholders' equity requirement or maintain its listing on the Nasdaq Capital Market.
• The company's stockholders' equity was $707,000 as of September 30, 2024, significantly below the required $2.5 million.

Risks

• There is a risk that Cara Therapeutics may not regain compliance with the stockholders' equity requirement by the May 19, 2025 deadline.
• The proposed merger with Tvardi Therapeutics, Inc. may not be completed, which could impact the company's ability to regain compliance.
• If the company fails to regain compliance, it could face delisting from the Nasdaq Capital Market.
• The combined company will need to meet initial listing requirements, including a higher minimum bid price and stockholders' equity, after the merger.

Future Outlook

The company is working to regain compliance with the stockholders' equity requirement by May 19, 2025, primarily through the proposed merger with Tvardi Therapeutics, Inc. However, there is no guarantee that the company will be successful in regaining compliance or maintaining its listing on the Nasdaq Capital Market.

Management Comments

• The company is making every effort to regain compliance prior to the extended deadline.
• The parties intend to satisfy each of the applicable listing criteria upon completion of the proposed Merger such that the combined company will remain listed on the Nasdaq Capital Market.

Industry Context

The document highlights the challenges faced by smaller biotech companies in maintaining Nasdaq listing compliance, particularly in terms of minimum bid price and stockholders' equity. The proposed merger with Tvardi is a common strategy for companies facing such challenges, aiming to strengthen their financial position and meet listing requirements.

Comparison to Industry Standards

• Many small-cap biotech companies face challenges in maintaining Nasdaq listing compliance, particularly regarding minimum bid price and stockholders' equity.
• Reverse stock splits are a common tactic used by companies to regain compliance with minimum bid price requirements, as seen with Cara Therapeutics' one-for-twelve split.
• Mergers and acquisitions are frequently used by companies to improve their financial position and meet listing requirements, similar to Cara's proposed merger with Tvardi.
• The minimum stockholders' equity requirement of $2.5 million is a standard benchmark for Nasdaq Capital Market listings, and Cara's $707,000 equity as of September 30, 2024, is significantly below this threshold.
• Other companies facing similar challenges include those in the biotech sector with limited revenue and high research and development costs, often relying on capital raises and strategic transactions to maintain their listing status.

Stakeholder Impact

• Shareholders face the risk of potential delisting if the company fails to regain compliance with Nasdaq requirements.
• Employees may be impacted by the uncertainty surrounding the company's future and the potential merger.
• Customers and suppliers may be affected by the company's financial instability and potential changes in operations.

Next Steps

• The company needs to complete the proposed merger with Tvardi Therapeutics, Inc.
• The company needs to regain compliance with the minimum stockholders' equity requirement by May 19, 2025.
• The combined company will need to meet initial listing requirements on the Nasdaq Capital Market after the merger.

Key Dates

Keywords

Nasdaq, compliance, minimum bid price, stockholders equity, reverse stock split, merger, delisting, Cara Therapeutics, Tvardi Therapeutics